Integra Lifesciences (IART) saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an increase from 70 to 74.
X This exclusive rating from Investor's Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating of above 80 as they begin their largest climbs. See if Integra Lifesciences can continue to show renewed price strength and hit that benchmark.
See How IBD Helps You Make More Money In Stocks
Integra Lifesciences is working on a consolidation with a 56.52 entry. See if the stock can break out in volume at least 40% above average.
Integra Lifesciences posted -2% earnings growth last quarter, while sales growth came in at 11%. Look for the next report on or around Feb. 23.
Integra Lifesciences earns the No. 18 rank among its peers in the Medical-Products industry group. Abiomed (ABMD), Align Technology (ALGN) and Edwards Lifesciences (EW) are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
